Search
Close this search box.

IDIOPATHIC PULMONARY FIBROSIS (IPF) IM027-068

ELIGIBILITY & REQUIREMENTS

  • Aged 40 or older
  • Confirmed diagnosis of Idiopathic Pulmonary Fibrosis (IPF)

WHAT'S INVOLVED

  • The trial will run for a minimum of 52 weeks and a maximum of 4 years in total.
  • A minimum of 14 clinic visits to the Institute for Respiratory Health at QEII Medical Centre, Nedlands.
  • A full health check by our doctors and nurses.
  • Reimbursement for travel expenses.
  • Personalised health care with our doctors and nurses.

STUDY OUTLINE

This international research study will test BMS-986278, an investigational drug called BMS-986278.

BMS-986278 is an oral LPA receptor 1 (LPA1) antagonist. It is being developed as a potential treatment for idiopathic pulmonary fibrosis (IPF) by its antagonistic effect on LPA1.

In this research study, you will get either BMS-986278 or placebo, which you will take in addition to your usual IPF medications.

To find out if this trial is suitable for you, please register below, or contact our Clinical Trials Team on 6151 0813 or email clinicaltrials@resphealth.uwa.edu.au.

PRINCIPAL INVESTIGATOR

Dr Vidya Navaratnam (Nedlands)

LOCATION

Level 2, 6 Verdun Street Nedlands (within the Harry Perkins Institute)

REGISTER YOUR INTEREST TODAY

* indicates required
Scroll to Top